Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
…, Y Minami, H Mocikova, E Morra, J Munoz, H Nagai… - The Lancet, 2019 - thelancet.com
Background Based on the encouraging activity and manageable safety profile observed in
a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …
a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …
[HTML][HTML] Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
…, T Watanabe, H Kato, H Nagai… - … England Journal of …, 1997 - Mass Medical Soc
Background Mutations of the p53 gene are associated with a poor prognosis in several
types of cancer. We investigated the prognostic importance of p53 mutations in patients with …
types of cancer. We investigated the prognostic importance of p53 mutations in patients with …
[PDF][PDF] Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B …
…, T Hotta, M Hutchings, T Nihashi, H Nagai - J Clin …, 2009 - scholar.archive.org
Purpose To systematically review the prognostic accuracy of fluorine-18-fluorodeoxyglucose
positron emission tomography (FDG-PET) for interim response assessment of patients with …
positron emission tomography (FDG-PET) for interim response assessment of patients with …
Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes
T Uchida, T Kinoshita, H Nagai… - Blood, The Journal …, 1997 - ashpublications.org
Previous studies have shown that the cyclin-dependent kinase inhibitor (CDKI) genes p15
INK4B and p16 INK4A are frequently inactivated by genetic alterations in many malignant …
INK4B and p16 INK4A are frequently inactivated by genetic alterations in many malignant …
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
…, C Nakaseko, T Ishikawa, M Matsumoto, H Nagai… - The Lancet, 2019 - thelancet.com
Background Maintenance therapy following autologous stem cell transplantation (ASCT)
can delay disease progression and prolong survival in patients with multiple myeloma. …
can delay disease progression and prolong survival in patients with multiple myeloma. …
18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review
…, T Nihashi, T Hotta, H Nagai - Journal of Nuclear …, 2008 - Soc Nuclear Med
Although studies have shown that 18 F-FDG PET, when used to assess the response of
malignant lymphoma after treatment, has a strong ability to predict relapse, its diagnostic …
malignant lymphoma after treatment, has a strong ability to predict relapse, its diagnostic …
The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin
T Watanabe, T Hotta, A Ichikawa, T Kinoshita, H Nagai… - 1994 - ashpublications.org
The expression of the murine double minute-2 (MDM2) gene, the product of which binds to
and inactivates p53, was studied in 60 patients with B-cell chronic lymphocytic leukemia (B-…
and inactivates p53, was studied in 60 patients with B-cell chronic lymphocytic leukemia (B-…
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone combined with high-dose methotrexate plus intrathecal chemotherapy for newly diagnosed …
…, K Matsue, K Sato, S Kusumoto, H Nagai… - The Lancet …, 2020 - thelancet.com
Background Intravascular large B-cell lymphoma (IVLBCL) is a rare disease for which there
is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (…
is no available standard treatment. We aimed to ascertain the safety and activity of R-CHOP (…
[HTML][HTML] Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma
PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase
inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent …
inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent …
Effects of low crystalline carbonate apatite on proliferation and osteoblastic differentiation of human bone marrow cells
H Nagai, M Kobayashi-Fujioka, K Fujisawa… - Journal of Materials …, 2015 - Springer
Carbonated apatite (CO 3 Ap) is the inorganic component of bone. We have proposed a new
method for the fabrication of CO 3 Ap blocks based on a dissolution-precipitation method …
method for the fabrication of CO 3 Ap blocks based on a dissolution-precipitation method …